PLX


Here’s Why Protalix (PLX) Stock Is Soaring Today

Protalix’s (NYSE:PLX) long-suffering bulls finally have reason to celebrate: The Israeli biotech firm announced this morning the expansion of its partnership with Chiesi. Protalix and …

Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis

Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from …

Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission

Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race …

Protalix Biotherapeutics Inc (PLX) Announces 3Q:17 Results and Provides Corporate Update

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its financial results for the nine months ended September 30, 2017 and provided a corporate update. “I am excited …

Protalix Biotherapeutics Inc (PLX) Shares Skyrocket – Here’s Why

It’s a very rewarding trading day for investors in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) with shares up over 35%, making the stock Wall Street’s …

Protalix Biotherapeutics Inc Fabry Disease Pivotal Program Shows Encouraging Potential: Rodman & Renshaw

Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% whirl down despite the biotech firm posting a …

Protalix Biotherapeutics Inc (PLX) Announces 2Q:17 Results and Provides Corporate Update

Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its financial results for the six months ended June 30, 2017 and provided a corporate update. “Substantial progress was …

Protalix Biotherapeutics Inc (PLX) Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference

Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced today that phase II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of …

Protalix Biotherapeutics Inc (PLX) to Convert Its Manufacturing Facility to a Multi-Product Facility

Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that a Supplemental New Drug Application (sNDA) submitted to the U.S.

Rodman & Renshaw Maintains Buy on Protalix Biotherapeutics Inc (PLX) Following Q1:17 Results

In a research report released Monday, Rodman & Renshaw analyst Ram Selvaraju reiterated a Buy rating on shares of Protalix Biotherapeutics Inc (NYSEMKT:PLX) with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts